Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Toxin.
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2018
Price : $35 *
At a glance
- Drugs Botulinum-antitoxin (Primary)
- Indications Botulism
- Focus Pharmacokinetics
- Sponsors Cangene Corporation
- 24 Jan 2018 Status changed from recruiting to completed.
- 24 Dec 2014 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2017, as reported by ClinicalTrials.gov.
- 24 Dec 2014 Planned End Date changed from 1 Jun 2017 to 1 Apr 2018, as reported by ClinicalTrials.gov.